Overview

In this immersive educational program, participants will expand their understanding of managing patients with Multiple Myeloma. This program utilizes the innovative AliveSim platform, offering real-life clinical case scenarios to work through in a low-stress environment with guidance from experts in the field of Oncology. Patient case scenarios created by our expert faculty will cover key oncology topics such as mechanism of action of new and emerging therapies for relapsed remitting multiple myeloma (RRMM), clinical evidence on utility and potential sequencing of new and emerging RRMM treatment approaches, disparities in RRMM and leveraging RRMM treatment advances to overcome treatment disparities. Interact with virtual patients and physicians as you practice managing Multiple Myeloma cancer with expert clinical mentoring.

Target Audience

This activity is designed to educate the MM care team including hematologists, oncologists, nurse practitioners, physician assistants, pharmacists, and nurse specialists.

Learning Objectives

1. Describe the mechanism-of-action of new and emerging therapies for the treatment of relapsed remitting multiple myeloma (RRMM)
2. Review clinical evidence on the utility and potential sequencing of new and emerging RRMM treatment approaches with or without planned transplant
3. Evaluate disparities in RRMM care and overall survival rates relative to treatment setting and ethnicity, particularly black patients
4. Leverage RRMM treatment advances to overcome treatment disparities and optimize patient outcomes